Types of drug metabolites
| Type | Mechanism | Example | Clinical relevance |
|---|---|---|---|
| Inactive metabolite | Detoxification product; no pharmacological activity | Aspirin → salicyluric acid | Usually no clinical concern; may affect urine drug tests |
| Active metabolite | Retains pharmacological activity (same or different mechanism) | Morphine → morphine-6-glucuronide; diazepam → desmethyldiazepam (nordazepam) | Prolongs drug effect; accumulates in renal impairment if renally cleared |
| Toxic metabolite | Causes direct organ toxicity or reactive intermediate formation | Paracetamol → NAPQI; cyclophosphamide → acrolein | Underlies overdose toxicity; genetic variation in detoxification pathway affects risk |
| Prodrug → active drug | Parent drug is inactive; metabolism produces the therapeutic agent | Codeine → morphine (CYP2D6); clopidogrel → active thiol (CYP2C19) | Pharmacogenomic variation directly affects efficacy and safety |
Phase I and phase II metabolism
Functionalisation
Introduces or exposes a reactive functional group (–OH, –COOH, –NH₂, –SH)
- Oxidation (CYP450 — most common)
- Reduction (carbonyl reductases, AKRs)
- Hydrolysis (esterases, amidases)
Conjugation
Adds a large polar molecule to increase water solubility for excretion
- Glucuronidation (UGT enzymes — most common)
- Sulfation (SULT)
- Glutathione conjugation (GST)
- Acetylation (NAT1/2)
- Methylation (COMT, TPMT)
Active metabolites vs inactive metabolites in drug therapy
Understanding the distinction between active metabolites and inactive metabolites is fundamental to predicting drug response. A drug metabolite that retains pharmacological activity can significantly extend the duration of drug effect, alter the safety profile, or — in the case of prodrugs — represent the actual therapeutic agent.
Active metabolites are produced when phase I or phase II metabolism generates a compound that binds to the same (or different) pharmacological target as the parent drug. Diazepam, for example, is metabolised to desmethyldiazepam (nordazepam), which has a half-life of 40-200 hours and contributes substantially to the prolonged sedation seen with benzodiazepine use. Morphine is conjugated by UGT2B7 to morphine-6-glucuronide (M6G), which is actually more potent than morphine itself and accumulates dangerously in patients with renal impairment.
Phase I metabolism (oxidation, reduction, hydrolysis via cytochrome P450 enzymes) introduces or unmasks reactive functional groups, while phase II metabolism (conjugation — glucuronidation, sulfation, acetylation) typically produces polar, inactive metabolites suitable for renal or biliary excretion. However, exceptions exist: morphine-6-glucuronide is a phase II product that is pharmacologically active, and NAPQI (from paracetamol) is a phase I product that is toxic. The FDA Drug Development and Drug Interactions Table catalogues known enzyme substrates and the metabolites they produce, while the NCBI StatPearls drug metabolism chapter provides detailed mechanistic coverage of both phases.